Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY01008
DRUG
2 trials
Sponsors
Luye Pharma Group Ltd.
, Shandong Boan Biotechnology Co., Ltd
Conditions
Metastatic Colorectal Cancer
Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer Recurrent
Phase 1
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
Completed
NCT05110118
Shandong Boan Biotechnology Co., Ltd
Metastatic Colorectal Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
Start: 2020-08-04
End: 2021-01-13
Updated: 2021-11-05
Phase 3
A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer
NCT03533127
Luye Pharma Group Ltd.
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
Start: 2017-11-27
End: 2020-12-28
Target: 648
Updated: 2018-07-10
Related Papers
A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
Expert Opinion on Biological Therapy
2021-12-16
1 citations
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
Cancer Communications
2021-06-29
25 citations